Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion
- 7 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 43 (6), 1372-1382
- https://doi.org/10.1038/s41401-021-00761-x
Abstract
SLL-039 (N-cyclopropylmethyl-7α−4′-(N’-benzoyl) amino-phenyl-6,14-endoethano-tetrahydronorthebaine) and SLL-1206 (N-cyclopropylmethyl-7α−3′-(p-methoxybenzyl) amino-phenyl-6,14-endoethano-tetrahydronorthebaine) are two 4,5-epoxymorphinan-based high selective κ receptor agonists that we recently discovered. In the present study we characterized their pharmacological properties in comparison with arylacetamide-based typical κ agonist U50,488H. We showed that both SLL-039 and SLL-1206 produced potent and long-lasting antinociceptive actions in three different rodent models of pain via activation of κ opioid receptor. In hot-plate assay, the antinociceptive potency of SLL-039 and SLL-1206 increased about 11-and 17.3-fold compared to U50,488H and morphine, respectively, with ED50 values of 0.4 mg/kg. Following repeated administration, SLL-1206, SLL-039, and U50,488H all developed analgesic tolerance tested in hot-plate assay. U50,488H and SLL-039 produced antipruritic effects in a dose-dependent manner, whereas SLL-1206 displayed some antipruritic effects only at very low doses. In addition, SLL-1206 was capable of decreasing morphine-induced physical dependence. More importantly, SLL-039 and SLL-1206 at effective analgesic doses did not cause sedation and conditioned place aversion (CPA), whereas U50,488H did. In comparison with SLL-039, SLL-1206 caused similar antinociceptive responses, but fewer sedation and CPA. In conclusion, our results suggest that SLL-039 and SLL-1206 have potential to be developed as novel analgesic agents, and 4,5-expoxymorphinan scaffold is an attractive structure for the development of selective κ agonists with fewer side effects.Keywords
This publication has 50 references indexed in Scilit:
- A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in ratsBehavioural Pharmacology, 2012
- Morphine and microRNA Activity: Is There a Relation with Addiction?Frontiers in Genetics, 2012
- The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abusePsychopharmacology, 2010
- Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in ratsPharmacology Biochemistry and Behavior, 2009
- Pharmacological Characterization of ATPM [(-)-3-Aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a Novel Mixed κ-Agonist and μ-Agonist/-Antagonist That Attenuates Morphine Antinociceptive Tolerance and Heroin Self-Administration BehaviorThe Journal of pharmacology and experimental therapeutics, 2009
- Cloning and bioinformatics of amphibian mu, delta, kappa, and nociceptin opioid receptors expressed in brain tissue: Evidence for opioid receptor divergence in mammalsNeuroscience Letters, 2007
- κ-Opioid System in Uremic PruritusJournal of the American Society of Nephrology, 2005
- Regulation of Opioid Receptor Trafficking and Morphine Tolerance by Receptor OligomerizationCell, 2002
- Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonistLife Sciences, 1999
- Properties of a selective kappa agonist, U-50,488HLife Sciences, 1982